Globus Medical ROE 2010-2022 | GMED

Current and historical return on equity (ROE) values for Globus Medical (GMED) over the last 10 years. Return on equity can be defined as the amount of net income returned as a percentage of shareholders equity. Return on equity measures a corporation's profitability by revealing how much profit a company generates with the money shareholders have invested.
Globus Medical ROE - Return on Equity Historical Data
Date TTM Net Income Shareholder's Equity Return on Equity
2022-09-30 $0.16B $1.76B 8.87%
2022-06-30 $0.16B $1.70B 8.93%
2022-03-31 $0.14B $1.79B 8.25%
2021-12-31 $0.15B $1.74B 8.95%
2021-09-30 $0.19B $1.72B 11.64%
2021-06-30 $0.18B $1.64B 12.02%
2021-03-31 $0.12B $1.56B 8.31%
2020-12-31 $0.10B $1.51B 7.26%
2020-09-30 $0.10B $1.42B 6.89%
2020-06-30 $0.09B $1.34B 6.54%
2020-03-31 $0.15B $1.36B 10.98%
2019-12-31 $0.16B $1.40B 11.77%
2019-09-30 $0.15B $1.34B 11.56%
2019-06-30 $0.14B $1.29B 11.79%
2019-03-31 $0.15B $1.24B 12.87%
2018-12-31 $0.16B $1.19B 14.11%
2018-09-30 $0.14B $1.14B 13.61%
2018-06-30 $0.14B $1.10B 13.41%
2018-03-31 $0.12B $1.03B 12.41%
2017-12-31 $0.11B $0.97B 11.75%
2017-09-30 $0.11B $0.94B 12.20%
2017-06-30 $0.11B $0.91B 12.65%
2017-03-31 $0.11B $0.87B 12.76%
2016-12-31 $0.10B $0.83B 13.12%
2016-09-30 $0.12B $0.81B 15.46%
2016-06-30 $0.12B $0.78B 16.18%
2016-03-31 $0.12B $0.75B 16.68%
2015-12-31 $0.11B $0.72B 17.08%
2015-09-30 $0.10B $0.67B 16.38%
2015-06-30 $0.10B $0.64B 16.69%
2015-03-31 $0.10B $0.61B 17.01%
2014-12-31 $0.09B $0.59B 17.15%
2014-09-30 $0.09B $0.55B 16.73%
2014-06-30 $0.08B $0.53B 17.03%
2014-03-31 $0.07B $0.50B 14.97%
2013-12-31 $0.07B $0.47B 15.54%
2013-09-30 $0.07B $0.45B 16.34%
2013-06-30 $0.06B $0.42B 16.19%
2013-03-31 $0.08B $0.41B 20.53%
2012-12-31 $0.07B $0.39B 21.53%
2012-09-30 $0.07B $0.36B 21.10%
2012-06-30 $0.07B $0.32B 30.02%
2012-03-31 $0.06B $0.30B 42.47%
2011-12-31 $0.06B $0.28B 79.43%
Sector Industry Market Cap Revenue
Medical Medical Instruments Manufacturing $7.483B $0.958B
Globus Medical, Inc. is a medical device company that develops and commercializes healthcare solutions for patients with musculoskeletal disorders. The company currently has its sales operations distributed across counties world wide. Its Musculoskeletal Solutions consist primarily of implantable devices, biologics, accessories, and unique surgical instruments, used in an expansive range of spinal, orthopedic and neurosurgical procedures. The spine products address the vast majority of conditions affecting the spine including degenerative conditions, deformity, tumors and trauma. Enabling Technologies are designed to enhance a surgeon's capabilities and streamline the complicated surgical procedures to be safer, less invasive, accurate and more reproducible to improve patient care and reduce radiation exposure for both patient and caregiver. The technology contains imaging, navigation and robotic assisted surgery solutions. It acquired all assets of StelKast, Inc. and Finnish engineering company Synoste Oy.
Stock Name Country Market Cap PE Ratio
Thermo Fisher Scientific (TMO) United States $220.806B 23.09
Edwards Lifesciences (EW) United States $47.328B 32.57
Alcon (ALC) Switzerland $34.365B 29.59
STERIS (STE) Ireland $19.157B 23.84
Teleflex (TFX) United States $11.379B 18.46
Fresenius Medical Care AG KGaA (FMS) Germany $9.600B 9.64
Penumbra (PEN) United States $8.008B 1916.82
Integer Holdings (ITGR) United States $2.426B 19.47
Glaukos (GKOS) United States $2.281B 0.00
Nevro (NVRO) United States $1.601B 0.00
Paragon 28 (FNA) United States $1.511B 0.00
AVANOS MEDICAL, INC (AVNS) United States $1.261B 17.96
Artivion (AORT) United States $0.546B 0.00